Open AccessEconomic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma
Author(s) -
Vusal Babashov,
Mehmet A. Begen,
Joy Mangel,
Gregory S. Zaric
Publication year - 2017
Publication title -
current oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.053
H-Index - 51
eISSN - 1718-7729
pISSN - 1198-0052
DOI - 10.3747/co.24.3369
Subject(s) - brentuximab vedotin , medicine , hodgkin lymphoma , lymphoma , oncology
We conducted a cost-effectiveness analysis of brentuximab vedotin for the treatment of relapsed and refractory Hodgkin lymphoma (hl) in the post-autologous stem-cell transplantation (asct) failure period, from the perspective of the Canadian health care payer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom